Physician profile
Morgan Gordon
NPI 1215531181
$3,631.54
in general payments reported to CMS, 2019-2025
27 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33.56 · 2022: $562 · 2023: $870 · 2024: $1,055 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,012 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.86 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $730.77 | 2022-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $379.80 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $305.64 | 2022-2024 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $254.47 | 2021-2025 | |
| Travere Therapeutics, INC. | $220.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $194.52 | 2022-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $173.51 | 2024-2025 | |
| Lilly USA, LLC | $167.06 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $162.23 | 2022-2025 | Veltassa |
| Amgen INC. | $135.71 | 2022-2025 | Tavneos |
| Horizon Therapeutics Plc | $134.12 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $118.95 | 2023-2025 | Crysvita |
| Akebia Therapeutics INC | $109.04 | 2022-2024 | Vafseo, Auryxia |
| Baxter Healthcare | $87.72 | 2023 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.56 | 2024 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vantive US Healthcare LLC | $56.45 | 2025 | Renal - Pd |
| Novo Nordisk INC | $49.94 | 2025 | Wegovy, Rybelsus, Ozempic |
| Opko Pharmaceuticals, LLC | $46.50 | 2022-2023 | Rayaldee |
| Ardelyx, INC. | $42.63 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.73 | 2023-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $38.31 | 2022 | |
| Ascendis Pharma Endocrinology INC | $24.54 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $21.33 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $20.67 | 2022 | |
| Medline Industries LP | $18.58 | 2024 | |
| Merck Sharp & Dohme LLC | $16.00 | 2021 | |
| Apellis Pharmaceuticals, INC. | $15.43 | 2025 | Empaveli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.